The investigational bispecific T-cell engager tarlatamab showed durable responses in patients with small-cell lung cancer (SCLC), particularly at lower doses, with encouraging survival outcomes. The therapy targeted cancer cells expressing DLL3 and demonstrated clinical activity in pretreated patients. Data from phase 1 and phase 2 trials showed overall response rates, progression-free survival, and overall survival. Patients receiving the 10 mg dose had better outcomes, including higher response rates and longer survival. Intracranial activity was observed in patients with brain metastases. Adverse events were common, including cytokine release syndrome. Further evaluation of tarlatamab and adverse event management is needed.
Source link
Tarlatamab Shows Promise in Tackling Previously Treated SCLC
